Personalized exercise program for older adults with sickle cell disease
Gerofit Exercise Intervention for Older Adults With Sickle Cell Disease (SICKLE-FIT Study)
This study is testing a personalized exercise program for older adults with sickle cell disease to see if it is safe and helpful for them.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Duke University Academic / other |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT05714098 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the feasibility, acceptability, and safety of a personalized exercise training program called Gerofit, specifically adapted for older adults aged 40 and above with sickle cell disease. Participants will undergo the Sickle Cell Disease Functional Assessment at baseline and every three months to monitor their progress. The study will also include interviews to identify barriers and facilitators to exercise, helping to optimize the intervention for better outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are older adults aged 40 and above who have a confirmed diagnosis of sickle cell disease.
Not a fit: Patients who are wheelchair-bound, oxygen-dependent, or have severe cognitive impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve the physical health and quality of life for older adults living with sickle cell disease.
How similar studies have performed: While the specific adaptation of the Gerofit program for sickle cell disease is novel, similar exercise interventions for chronic conditions have shown promising results in improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have a diagnosis of sickle cell disease (any genotype) confirmed by hemoglobin electrophoresis, high performance liquid chromatography, or genotyping * Understand and speak fluent English. Exclusion Criteria: * Diagnosed with moderate or severe cognitive impairment based on ICD-10 codes or report from their outpatient provider * Unable to self-consent * Wheelchair-bound * Successfully treated with hematopoietic stem cell transplantation for SCD * Have moderate to severe uncorrected visual or auditory impairment * Oxygen-dependent * Pregnant * Have severe avascular necrosis requiring an assist device * Unstable cardiac disease.
Where this trial is running
Durham, North Carolina
- Duke University — Durham, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Charity I Oyedeji, MD — Duke University
- Study coordinator: Charity I Oyedeji, MD
- Email: charity.oyedeji@duke.edu
- Phone: 9196840628
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.